Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retina

Free Radical Biology and Medicine

Volumn 53, Issue 1, 2012, Pages 64-71

  Song, Delu ^a,b   Song, Ying ^a   Hadziahmetovic, Majda ^a   Zhong, Yong ^b   Dunaief, Joshua L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Chelator; Deferiprone; Iron; Light damage; Retinal degeneration

Indexed keywords

3 NITROTYROSINE; CERULOPLASMIN; COMPLEMENT COMPONENT C3; DEFERIPRONE; FERRITIN; HEME OXYGENASE 1; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENT LIGHTING; HISTOPATHOLOGY; LIGHT EXPOSURE; MICROGLIA; MOUSE; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; APOPTOSIS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IN SITU NICK-END LABELING; IRON CHELATING AGENTS; LIGHT; MICE; MICE, INBRED A; MICROGLIA; OXIDATIVE STRESS; PHOTORECEPTOR CELLS, VERTEBRATE; PYRIDONES; RADIATION INJURIES, EXPERIMENTAL; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL DEGENERATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MUS; PRENANTHELLA EXIGUA;

EID: 84861600077     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.04.020     Document Type: Article

References (59)

1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report no. 8. Arch. Ophthalmol. 119:1417-1436; 2001.
2. H.R. Taylor Ultraviolet radiation and the eye: an epidemiologic study Trans. Am. Ophthalmol. Soc. 87 1989 802 853
3. Taylor, H. R.; Munoz, B.; West, S.; Bressler, N. M.; Bressler, S. B.; Rosenthal, F. S. Visible light and risk of age-related macular degeneration. Trans. Am. Ophthalmol. Soc. 88:163-73; 1990, discussion 173-8.
4. R.L. Marlor, B.R. Blais, F.R. Preston, and D.G. Boyden Foveomacular retinitis, an important problem in military medicine: epidemiology Invest. Ophthalmol 12 1973 5 16
5. R.W. Young Solar radiation and age-related macular degeneration Surv. Ophthalmol. 32 1988 252 269
6. W.K. Noell, V.S. Walker, B.S. Kang, and S. Berman Retinal damage by light in rats Invest. Ophthalmol 5 1966 450 473
7. S. Shahinfar, D.P. Edward, and M.O. Tso A pathologic study of photoreceptor cell death in retinal photic injury Curr. Eye Res. 10 1991 47 59
8. R.E. Marc, B.W. Jones, C.B. Watt, F. Vazquez-Chona, D.K. Vaughan, and D.T. Organisciak Extreme retinal remodeling triggered by light damage: implications for age related macular degeneration Mol. Vis. 14 2008 782 806
9. D.T. Organisciak, R.M. Darrow, Y.I. Jiang, G.E. Marak, and J.C. Blanks Protection by dimethylthiourea against retinal light damage in rats Invest. Ophthalmol. Vis. Sci. 33 1992 1599 1609
10. I. Ranchon, S. Chen, K. Alvarez, and R.E. Anderson Systemic administration of phenyl-N-tert-butylnitrone protects the retina from light damage Invest. Ophthalmol. Vis. Sci. 42 2001 1375 1379
11. C.M. Li, B.H. Chung, J.B. Presley, G. Malek, X. Zhang, N. Dashti, L. Li, J. Chen, K. Bradley, H.S. Kruth, and C.A. Curcio Lipoprotein-like particles and cholesteryl esters in human Bruchs membrane: initial characterization Invest. Ophthalmol. Vis. Sci. 46 2005 2576 2586
12. A. Takeda, J.Z. Baffi, M.E. Kleinman, W.G. Cho, M. Nozaki, K. Yamada, H. Kaneko, R.J. Albuquerque, S. Dridi, K. Saito, B.J. Raisler, S.J. Budd, P. Geisen, A. Munitz, B.K. Ambati, M.G. Green, T. Ishibashi, J.D. Wright, A.A. Humbles, C.J. Gerard, Y. Ogura, Y. Pan, J.R. Smith, S. Grisanti, M.E. Hartnett, M.E. Rothenberg, and J. Ambati CCR3 is a target for age-related macular degeneration diagnosis and therapy Nature 460 2009 225 230
13. S.W. Cousins, D.G. Espinosa-Heidmann, and K.G. Csaky Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization Arch. Ophthalmol. 122 2004 1013 1018
14. C.W. Spraul, G.E. Lang, and H.E. Grossniklaus Morphometric analysis of the choroid, Bruchs membrane, and retinal pigment epithelium in eyes with age-related macular degeneration Invest. Ophthalmol. Vis. Sci. 37 1996 2724 2735
15. L.A. Donoso, D. Kim, A. Frost, A. Callahan, and G. Hageman The role of inflammation in the pathogenesis of age-related macular degeneration Surv. Ophthalmol. 51 2006 137 152
16. Y. Wu, E. Yanase, X. Feng, M.M. Siegel, and J.R. Sparrow Structural characterization of bisretinoid A2E photocleavage products and implications for age-related macular degeneration Proc. Natl. Acad. Sci. USA 107 2010 7275 7280
17. E.G. McGeer, A. Klegeris, and P.L. McGeer Inflammation, the complement system and the diseases of aging Neurobiol. Aging 26 Suppl. 1 2005 94 97
18. J.G. Hollyfield, V.L. Bonilha, M.E. Rayborn, X. Yang, K.G. Shadrach, L. Lu, R.L. Ufret, R.G. Salomon, and V.L. Perez Oxidative damage-induced inflammation initiates age-related macular degeneration Nat. Med. 14 2008 194 198
19. J. Cai, K.C. Nelson, M. Wu, P. Sternberg Jr, and D.P. Jones Oxidative damage and protection of the RPE Prog. Retin. Eye Res. 19 2000 205 221
20. M. Cano, R. Thimmalappula, M. Fujihara, N. Nagai, M. Sporn, A.L. Wang, A.H. Neufeld, S. Biswal, and J.T. Handa Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and age-related macular degeneration Vis. Res. 50 2010 652 664
21. The Age-Related Eye Disease Study: a clinical trial of zinc and antioxidants - Age-Related Eye Disease Study Report no. 2. J. Nutr. 130:1516S-1519SS;2000.
22. J.K. Shen, A. Dong, S.F. Hackett, W.R. Bell, W.R. Green, and P.A. Campochiaro Oxidative damage in age-related macular degeneration Histol. Histopathol. 22 2007 1301 1308
23. M. Hadziahmetovic, T. Dentchev, Y. Song, N. Haddad, X. He, P. Hahn, D. Pratico, R. Wen, Z.L. Harris, J.D. Lambris, J. Beard, and J.L. Dunaief Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD Invest. Ophthalmol. Vis. Sci. 49 2008 2728 2736
24. J.L. Dunaief Iron induced oxidative damage as a potential factor in age-related macular degeneration: the Cogan Lecture Invest. Ophthalmol. Vis. Sci. 47 2006 4660 4664
25. P. Hahn, A.H. Milam, and J.L. Dunaief Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruchs membrane Arch. Ophthalmol. 121 2003 1099 1105
26. R.W. Wong, D.C. Richa, P. Hahn, W.R. Green, and J.L. Dunaief Iron toxicity as a potential factor in AMD Retina 27 2007 997 1003
27. M. Hadziahmetovic, Y. Song, N. Wolkow, J. Iacovelli, S. Grieco, J. Lee, A. Lyubarsky, D. Pratico, J. Connelly, M. Spino, Z.L. Harris, and J.L. Dunaief The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration Invest. Ophthalmol. Vis. Sci. 52 2011 959 968
28. Z.L. Li, S. Lam, and M.O. Tso Desferrioxamine ameliorates retinal photic injury in albino rats Curr. Eye Res. 10 1991 133 144
29. V. Lakhanpal, S.S. Schocket, and R. Jiji Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy Ophthalmology 91 1984 443 451
30. N. Boddaert, Q.S.K.H. Le, A. Rotig, A. Leroy-Willig, S. Gallet, F. Brunelle, D. Sidi, J.C. Thalabard, A. Munnich, and Z.I. Cabantchik Selective iron chelation in Friedreich ataxia: biologic and clinical implications Blood 110 2007 401 408
31. S.V. Shah, and M.M. Rajapurkar The role of labile iron in kidney disease and treatment with chelation Hemoglobin 33 2009 378 385
32. L. Chen, W. Wu, T. Dentchev, Y. Zeng, J. Wang, I. Tsui, J.W. Tobias, J. Bennett, D. Baldwin, and J.L. Dunaief Light damage induced changes in mouse retinal gene expression Exp. Eye Res. 79 2004 239 247
33. S.L. Zeger, and K.Y. Liang Longitudinal data analysis for discrete and continuous outcomes Biometrics 42 1986 121 130
34. J.L. Dunaief, T. Dentchev, G.S. Ying, and A.H. Milam The role of apoptosis in age-related macular degeneration Arch. Ophthalmol. 120 2002 1435 1442
35. L. Chen, T. Dentchev, R. Wong, P. Hahn, R. Wen, J. Bennett, and J.L. Dunaief Increased expression of ceruloplasmin in the retina following photic injury Mol. Vis. 9 2003 151 158
36. T.W. Mittag, A.U. Bayer, and M.M. La VAIL Light-induced retinal damage in mice carrying a mutated SOD I gene Exp. Eye Res. 69 1999 677 683
37. M. Wang, T.T. Lam, J. Fu, and M.O. Tso TEMPOL, a superoxide dismutase mimic, ameliorates light-induced retinal degeneration Res. Commun. Mol. Pathol. Pharmacol. 89 1995 291 305
38. Y.Q. Ni, G.Z. Xu, W.Z. Hu, L. Shi, Y.W. Qin, and C.D. Da Neuroprotective effects of naloxone against light-induced photoreceptor degeneration through inhibiting retinal microglial activation Invest. Ophthalmol. Vis. Sci. 49 2008 2589 2598
39. Collier, R. J.; Wang, Y.; Smith, S. S.; Martin, E.; Ornberg, R.; Rhoades, K.; Romano, C. Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest. Ophthalmol. Vis. Sci.; 2011.
40. C. Zhang, J.K. Shen, T.T. Lam, H.Y. Zeng, S.K. Chiang, F. Yang, and M.O. Tso Activation of microglia and chemokines in light-induced retinal degeneration Mol. Vis. 11 2005 887 895
41. B. Rohrer, Y. Guo, K. Kunchithapautham, and G.S. Gilkeson Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage Invest. Ophthalmol. Vis. Sci. 48 2007 5282 5289
42. S. Osaki, D.A. Johnson, and E. Frieden The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum J. Biol. Chem. 241 1966 2746 2751
43. B.N. Patel, R.J. Dunn, S.Y. Jeong, Q. Zhu, J.P. Julien, and S. David Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury J. Neurosci. 22 2002 6578 6586
44. R. Tenhunen, H.S. Marver, and R. Schmid The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase Proc. Natl. Acad. Sci. USA 61 1968 748 755
45. J.S. Beckman, H. Ischiropoulos, L. Zhu, M.V der Woerd, C. Smith, J. Chen, J. Harrison, J.C. Martin, and M. Tsai Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite Arch. Biochem. Biophys. 298 1992 438 445
46. G.J. Kontoghiorghes, A. Efstathiou, M. Kleanthous, Y. Michaelides, and A. Kolnagou Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions Hemoglobin 33 2009 386 397
47. G.J. Kontoghiorghes, A. Kolnagou, C.T. Peng, S.V. Shah, and A. Aessopos Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases Expert Opin. Drug Saf. 9 2010 201 206
48. G. Liu, P. Men, G. Perry, and M.A. Smith Nanoparticle and iron chelators as a potential novel Alzheimer therapy Methods Mol. Biol. 610 2010 123 144
49. J.R. Boelaert, G.A. Weinberg, and E.D. Weinberg Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management Infect. Agents Dis. 5 1996 36 46
50. R.R. Hidajat, J.L. McLay, D.H. Goode, and R.L. Spearing EOG as a monitor of desferrioxamine retinal toxicity Doc. Ophthalmol. 109 2004 273 278
51. M. Karimi, A.A. Asadi-Pooya, B. Khademi, K. Asadi-Pooya, and H. Yarmohammadi Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine Acta Haematol. 108 2002 79 83
52. J.S. Baath, W.C. Lam, M. Kirby, and A. Chun Deferoxamine-related ocular toxicity: incidence and outcome in a pediatric population Retina 28 2008 894 899
53. A.M. Fredenburg, R.K. Sethi, D.D. Allen, and R.A. Yokel The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1′ol]-2-methyl-3-hydroxypyridin-4- one in the rat Toxicology 108 1996 191 199
54. G.J. Kontoghiorghes, K. Neocleous, and A. Kolnagou Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine Drug Saf. 26 2003 553 584
55. Y.S. Sohn, W. Breuer, A. Munnich, and Z.I. Cabantchik Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications Blood 111 2008 1690 1699
56. M.D. Cappellini, and P. Pattoneri Oral iron chelators Annu. Rev. Med. 60 2009 25 38
57. R. Galanello Campus, S. Deferiprone chelation therapy for thalassemia major Acta Haematol. 122 2009 155 164
58. M.D. Cappellini, and A. Piga Current status in iron chelation in hemoglobinopathies Curr. Mol. Med. 8 2008 663 674
59. Obolensky, A.; Berenshtein, E.; Lederman, M.; Bulvik, B.; Alper-Pinus, R.; Yaul, R.; Deleon, E.; Chowers, I.; Chevion, M.; Banin, E. Zinc-desferrioxamine attenuates retinal degeneration in the rd10 mouse model of retinitis pigmentosa. Free Radic. Biol. Med.; 2011.